Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma: a Multicenter, Non-interventional, Retrospective Survey
Because State Food and Drug Administration (SFDA) exempted manufacturers from conducting
clinical trials of Sunitinib in China, overall efficacy and safety data of Sunitinib in
Chinese patients with renal cell carcinoma were deficiency. The investigators carried out
this research project will be sufficient evidence, and help clinicians in China to make
decision in real daily practice.
Observational
Observational Model: Cohort, Time Perspective: Retrospective
Disease control rate (DCR)
To determine the Disease control rate (DCR) defined as the percentage of patients who have a partial response (CR) or complete response (PR) to Sunitinib plus those whose disease is stable (DS). To determine the Objective Responsive Rate (ORR) defined as the percentage of patients who have a partial response (PR) or complete response (CR) to Sunitinib.
2008-2011 (up to 3 years)
No
Zhangqun Ye, MD
Principal Investigator
Tongji Hospital
China: Food and Drug Administration
CFC20110815
NCT01441661
November 2007
June 2012
Name | Location |
---|